Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Epidemiologic studies have consistently shown a mortality advantage among patients with hematocrits in the 30% to 36% range, and the NKF-DOQI Work Group on Anemia Management recommended a target hematocrit of 33% to 36% based on the expert panels' detailed literature review
Related products Essence & Serum Numbuzin No
If youre in the Vaughan, Woodbridge, or Greater Toronto Area and ready to explore whether GLP-1 agonists could be part of your success story, wed love to help
Most modern clinics use the without-DAC form
US$ 22.89
US$ 24.77
US$ 29.66
US$ 26.75
